SPA
YMAB

Sherbrooke Park Advisers’s Y-mAbs Therapeutics YMAB Stock Holding History

Sherbrooke Park Advisers’s Portfolio YMAB Stock Details YMAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-23,647
Closed -$286K – 1319
2024
Q2 		$286K Buy
+23,647
New +$319K 0.05% 646

Other funds holding YMAB

PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

Sherbrooke Park Advisers's YMAB Position: Q3 2024 in Review

Sherbrooke Park Advisers sold out of Y-mAbs Therapeutics (YMAB) in Q3 2024, closing a stake of 23,647 shares — an estimated $286K sold.

Sherbrooke Park Advisers first reported a position in YMAB in Q2 2024 and held it in 1 quarter. The position peaked at $286K in Q2 2024. 105 funds tracked by Wall St. Rank hold YMAB as of Q3 2024.

  • Sherbrooke Park Advisers reported no remaining Y-mAbs Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Sherbrooke Park Advisers sold 23,647 Y-mAbs Therapeutics shares in Q3 2024, an estimated $286K.
  • Sherbrooke Park Advisers first reported a position in Y-mAbs Therapeutics in Q2 2024 and held it in 1 quarter.
  • Sherbrooke Park Advisers's Y-mAbs Therapeutics position peaked at $286K in Q2 2024.
  • 105 funds tracked by Wall St. Rank held Y-mAbs Therapeutics as of Q3 2024.

Based on Sherbrooke Park Advisers's 13F filing for Q3 2024, filed 14 Nov 2024.